Alteration of transthyretin and thyroxine-binding globulin in major depressive disorder: multiple reaction monitoring-based proteomic analysis

Table 5 Plasma protein concentrations (fmol/μL) at baseline and at 6 weeks after mirtazapine treatment

Protein	Responder			Nonresponder			Responsiveness
	Mean ± SD		Uni-P^a	Mean ± SD		Uni-P^a	Uni-P^b	Multi-P^c
	At baseline	At 6 week	Uni-P^a	At baseline	At 6 week	Uni-P^a	Uni-P^b	Multi-P^c
N	22			21
AGP1	7872 ± 2719	6967 ± 1610	0.087	7360 ± 3620	6460 ± 1356	0.448	0.280	0.462
HGFA	4.48 ± 1.84	4.21 ± 1.36	0.449	3.79 ± 1.51	4.73 ± 1.83	0.015	0.191	0.270
LBP	31.4 ± 16.2	33.4 ± 12.7	0.219	30.0 ± 10.7	30.8 ± 9.64	0.629	0.585	0.772
Prothrombin	1450 ± 284	1549 ± 383	0.302	1528 ± 412	1486 ± 395	0.657	0.057	0.246
SeP	146 ± 26.2	154 ± 40.4	0.389	157 ± 51.4	158 ± 40.1	0.974	0.397	0.395
TBG	120 ± 28.6	139 ± 38.3	0.007	112 ± 36.2	118 ± 22.5	0.725	0.552	0.511
Transthyretin	6294 ± 1783	6968 ± 2063	0.095	6841 ± 2016	7425 ± 1954	0.209	0.351	0.379

HAM-D Hamilton Depression Rating Scale, SD standard deviation
^aP-value from Wilcoxon signed rank test or paired T-test between at baseline and at 6 weeks in each response group
^bP-value from Mann–Whitney test or T-test between responders and nonresponders at baseline
^cMultivariable P-value from partial Spearman correlation analysis including clinical variables with P < 0.020 (HAM-D score at baseline, and duration of current episode)

ISSN: 1479-5876